Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2019-06-26 Director's Dealing
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - TM 2 pages 404.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director or related parties, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific notification of director share transactions.
2019-06-26 English
Change of Director's Interest Notice - TM 2 pages 405.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired and held, nature of the interest, and dates. This is a formal notification of a director's personal share transactions. The document length is 3517 characters, which is typical for such notices. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2019-06-12 English
Appendix 3B LTIP 12 pages 786.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including the number of shares issued, issue price, terms, and compliance with ASX rules. It includes sections on placement capacity calculations under ASX Listing Rules 7.1 and 7.1A, which relate to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but a regulatory announcement about capital raising and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the share issue, not just a brief notice or a report publication announcement.
2019-05-30 English
Appendix 3B 5 pages 385.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of 200,000 unlisted options, their terms, issue price, purpose, and compliance with ASX listing rules. The document is a formal announcement of a new securities issue and application for quotation on the ASX, consistent with the Appendix 3B form used in Australian securities regulation for new issue announcements. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits the category of a Capital/Financing Update (CAP). The document length (6859 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2019-05-26 English
Change of Director's Interest Notice 2 pages 460.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options acquired, disposed, and held before and after the change. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The document length is 3916 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is a full financial report or other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2019-05-26 English
Chairman's Address to Shareholders 4 pages 338.3KB
AGM Information Classification · 95% confidence The document is a transcript or script of the Annual General Meeting (AGM) of Cyclopharm Limited held on 21 May 2019. It includes the Chairman's opening remarks, introduction of directors and management, a review of the company's achievements during the past year, financial performance highlights, strategic growth objectives, and future outlook. The document references the Notice of Annual General Meeting, Financial Statements, Independent Auditor's Report, Directors' Report, and other meeting materials as being tabled and available for review, but these are not included in the text itself. The content is focused on the proceedings and presentations at the AGM rather than being a full annual report or financial statement. The length (10,892 characters) and detailed narrative of the meeting support classification as AGM Information. Therefore, the document fits the category of AGM Information (AGM-R).
2019-05-20 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.